TapewireFind a company

person · Reporting owner

Pons Jaume

Disclosed activity across 1 company

Tapewire entity
82914
SEC CIK
0001816977

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040PRESIDENT & CSOFebruary 19, 2025February 21, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALX ONCOLOGY HOLDINGS INC

Report date February 19, 2025 · Filed February 21, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect579,388 Reported balance After 2025-02-19 transaction · row 1
1 source row

Row 1 · 2025-02-19 · Sale · Disposed 1,326 · Balance 579,388

F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 21, 2021 Filed Jun 22, 2021 16:26 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 10,353 $58.92 $609,975.98
Disclosure

SEC source: 0001209191-21-042395 · doc4.xml · nonDerivative · entry 2

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 511,246

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.58 to $59.22, inclusive.

Read SEC document
June 21, 2021 Filed Jun 22, 2021 16:26 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 6,347 $58.06 $368,504.28
Disclosure

SEC source: 0001209191-21-042395 · doc4.xml · nonDerivative · entry 1

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 521,599

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.56 to $58.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Read SEC document
May 19, 2021 Filed May 20, 2021 19:52 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 979 $56.71 $55,514.59
Disclosure

SEC source: 0001209191-21-034662 · doc4.xml · nonDerivative · entry 3

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 527,946

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F4 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.59 to $56.83, inclusive.

Read SEC document
May 19, 2021 Filed May 20, 2021 19:52 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 15,221 $55.69 $847,659.01
Disclosure

SEC source: 0001209191-21-034662 · doc4.xml · nonDerivative · entry 2

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 528,925

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F3 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.50 to $56.35, inclusive.

Read SEC document
May 19, 2021 Filed May 20, 2021 19:52 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 500 $54.20 $27,102.40
Disclosure

SEC source: 0001209191-21-034662 · doc4.xml · nonDerivative · entry 1

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 544,146

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.53 to $54.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4.

Read SEC document
April 19, 2021 Filed Apr 21, 2021 16:14 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 837 $60.48 $50,617.83
Disclosure

SEC source: 0000899243-21-016591 · doc4.xml · nonDerivative · entry 5

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 544,646

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.27 to $61.01, inclusive.

Read SEC document
April 19, 2021 Filed Apr 21, 2021 16:14 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 663 $59.52 $39,460.04
Disclosure

SEC source: 0000899243-21-016591 · doc4.xml · nonDerivative · entry 4

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 545,483

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.21 to $60.20, inclusive.

Read SEC document
April 19, 2021 Filed Apr 21, 2021 16:14 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 2,914 $58.36 $170,054.05
Disclosure

SEC source: 0000899243-21-016591 · doc4.xml · nonDerivative · entry 3

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 546,146

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.125 to $58.90, inclusive.

Read SEC document
April 19, 2021 Filed Apr 21, 2021 16:14 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 6,956 $57.73 $401,568.49
Disclosure

SEC source: 0000899243-21-016591 · doc4.xml · nonDerivative · entry 2

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 549,060

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.11 to $58.09, inclusive.

Read SEC document
April 19, 2021 Filed Apr 21, 2021 16:14 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 5,330 $56.42 $300,732.99
Disclosure

SEC source: 0000899243-21-016591 · doc4.xml · nonDerivative · entry 1

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 556,016

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.10 to $57.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4.

Read SEC document
March 25, 2021 Filed Mar 26, 2021 21:39 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 10,000 $0.00 Strike: $0.99 $0.00
Disclosure

SEC source: 0000899243-21-013739 · doc4.xml · derivative · entry 2

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,179

Underlying: Common Stock · 10,000 shares

Expires 2027-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on May 1, 2017.

Read SEC document
March 25, 2021 Filed Mar 26, 2021 21:39 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 Exercise / conversionCommon Stock 10,000 $0.99 $9,900.00
Disclosure

SEC source: 0000899243-21-013739 · doc4.xml · nonDerivative · entry 1

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 561,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 22, 2021 Filed Mar 24, 2021 16:05 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 16,700 $0.00 Strike: $1.91 $0.00
Disclosure

SEC source: 0000899243-21-013283 · doc4.xml · derivative · entry 9

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,019

Underlying: Common Stock · 16,700 shares

Expires 2029-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on June 16, 2019.

Read SEC document
March 22, 2021 Filed Mar 24, 2021 16:05 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 600 $70.12 $42,074.58
Disclosure

SEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 8

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 551,346

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.20, inclusive.

Read SEC document
March 22, 2021 Filed Mar 24, 2021 16:05 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 9,200 $69.77 $641,857.32
Disclosure

SEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 7

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 551,946

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.97 to $69.95, inclusive.

Read SEC document
March 22, 2021 Filed Mar 24, 2021 16:05 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 2,700 $68.27 $184,329.00
Disclosure

SEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 6

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 561,146

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.81 to $68.80, inclusive.

Read SEC document
March 22, 2021 Filed Mar 24, 2021 16:05 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 1,500 $67.18 $100,773.45
Disclosure

SEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 5

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 563,846

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.81 to $67.79, inclusive.

Read SEC document
March 22, 2021 Filed Mar 24, 2021 16:05 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 600 $66.33 $39,795.00
Disclosure

SEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 4

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 565,346

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.80 to $66.69, inclusive.

Read SEC document
March 22, 2021 Filed Mar 24, 2021 16:05 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 900 $64.98 $58,486.14
Disclosure

SEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 3

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 565,946

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.64 to $65.25, inclusive.

Read SEC document
March 22, 2021 Filed Mar 24, 2021 16:05 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 SaleCommon Stock 1,200 $63.79 $76,545.00
Disclosure

SEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 2

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 566,846

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.33 to $64.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (8) to this Form 4.

Read SEC document
March 22, 2021 Filed Mar 24, 2021 16:05 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 Exercise / conversionCommon Stock 16,700 $1.91 $31,897.00
Disclosure

SEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 1

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 568,046

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 26, 2021 Filed Jan 28, 2021 06:01 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 Exercise / conversionEmployee Stock Option (right to buy) · Derivative 10,000 $0.00 Strike: $0.99 $0.00
Disclosure

SEC source: 0000899243-21-003565 · doc4.xml · derivative · entry 2

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,179

Underlying: Common Stock · 10,000 shares

Expires 2027-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on May 1, 2017.

Read SEC document
January 26, 2021 Filed Jan 28, 2021 06:01 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 Exercise / conversionCommon Stock 10,000 $0.99 $9,900.00
Disclosure

SEC source: 0000899243-21-003565 · doc4.xml · nonDerivative · entry 1

Pons Jaume · CIK 0001816977 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 551,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:54 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries C Convertible Preferred Stock · Derivative 5,264 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019904 · doc4.xml · derivative · entry 4

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,264 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:54 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries A Convertible Preferred Stock · Derivative 1,803 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019904 · doc4.xml · derivative · entry 3

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,803 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:54 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionSeries A Convertible Preferred Stock · Derivative 20,225 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019904 · doc4.xml · derivative · entry 2

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,225 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:54 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 ConversionCommon Stock 27,292 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019904 · doc4.xml · nonDerivative · entry 1

Pons Jaume · CIK 0001816977 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 541,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F4 · balance_after: Includes 4,982 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.

Read SEC document
July 16, 2020 Filed Jul 17, 2020 19:00 UTC ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 GrantEmployee Stock Option (right to buy) · Derivative 272,771 $0.00 Strike: $19.00 $0.00
Disclosure

SEC source: 0000899243-20-019572 · doc4.xml · derivative · entry 1

Pons Jaume · CIK 0001816977 · Director · President &CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,771

Underlying: Common Stock · 272,771 shares

Expires 2030-07-16

F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 16, 2020.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.